Federated Hermes Inc. Boosts Stake in Zenas BioPharma, Inc. $ZBIO

Federated Hermes Inc. increased its stake in Zenas BioPharma, Inc. (NASDAQ:ZBIO) by 60.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,861,838 shares of the company’s stock after acquiring an additional 703,838 shares during the period. Federated Hermes Inc. owned about 4.45% of Zenas BioPharma worth $18,041,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its stake in Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after purchasing an additional 2,679 shares during the last quarter. Intech Investment Management LLC raised its holdings in shares of Zenas BioPharma by 13.9% during the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock valued at $128,000 after buying an additional 1,607 shares in the last quarter. Rhumbline Advisers lifted its position in Zenas BioPharma by 71.3% in the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after buying an additional 8,207 shares during the last quarter. Nuveen LLC purchased a new stake in Zenas BioPharma in the first quarter worth approximately $250,000. Finally, Geode Capital Management LLC boosted its stake in Zenas BioPharma by 4.6% in the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after buying an additional 16,461 shares in the last quarter.

Zenas BioPharma Trading Up 2.4%

Shares of ZBIO opened at $39.10 on Thursday. The stock has a market capitalization of $2.10 billion, a P/E ratio of -5.53 and a beta of -1.61. Zenas BioPharma, Inc. has a twelve month low of $5.83 and a twelve month high of $41.50. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37. The firm has a fifty day simple moving average of $31.66 and a two-hundred day simple moving average of $20.54.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Wall Street Analyst Weigh In

ZBIO has been the topic of several research reports. Wall Street Zen upgraded shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Wedbush reiterated an “outperform” rating and issued a $45.00 target price (up previously from $40.00) on shares of Zenas BioPharma in a research report on Monday, October 27th. Jefferies Financial Group reissued a “buy” rating and issued a $52.00 price target on shares of Zenas BioPharma in a research note on Monday, October 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Zenas BioPharma in a research report on Thursday, October 30th. Finally, Evercore ISI began coverage on Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Zenas BioPharma currently has an average rating of “Moderate Buy” and a consensus price target of $46.29.

Insider Buying and Selling at Zenas BioPharma

In other Zenas BioPharma news, major shareholder Sr One Capital Management, Llc acquired 126,315 shares of the company’s stock in a transaction on Thursday, October 9th. The stock was acquired at an average price of $19.00 per share, for a total transaction of $2,399,985.00. Following the acquisition, the insider owned 1,917,895 shares in the company, valued at $36,440,005. This represents a 7.05% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Patrick G. Enright bought 105,265 shares of Zenas BioPharma stock in a transaction dated Thursday, October 9th. The shares were acquired at an average cost of $19.00 per share, for a total transaction of $2,000,035.00. Following the completion of the purchase, the director directly owned 1,832,669 shares of the company’s stock, valued at approximately $34,820,711. This trade represents a 6.09% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 923,035 shares of company stock worth $17,628,163 over the last three months. 16.50% of the stock is owned by corporate insiders.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.